PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

Key Terms

oligonucleotide therapies medical

Short pieces of genetic material designed to change how a specific gene behaves, acting like a targeted instruction or patch that can block, boost, or reroute a faulty cellular message. Investors care because these therapies promise highly specific treatments for diseases with unmet needs, which can command premium pricing and rapid value creation, but they also carry scientific, regulatory, manufacturing and patent risks that affect potential returns.

ipo financial

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

BOSTON--(BUSINESS WIRE)-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies.

“Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and strategic partnerships,” said James McArthur, PhD, President and Chief Executive Officer of PepGen. “We are excited to welcome him to PepGen’s executive leadership team as we continue to make significant progress advancing our PGN-EDODM1 program and prepare for the anticipated 2026 readouts from the 5 mg/kg and 10 mg/kg cohorts in our FREEDOM2-EDODM1 multiple ascending dose study in DM1 patients.”

Mr. Vittiglio joins PepGen after providing extensive consulting support to the Company in 2025. He most recently served as Chief Business and Legal Officer and Corporate Secretary at bluebird bio, where he led global legal, compliance, and business development; supported the approval and launch of three U.S. gene therapy products; advanced ex-U.S. partnering; and completed more than $400 million in financings. Prior to bluebird, he served as Chief Business and Legal Officer at Finch Therapeutics, guiding the company’s IPO, building its public-company governance and compliance functions, and overseeing a global IP portfolio of more than 50 patent families. Previously, he was Chief Business Officer and General Counsel at AMAG Pharmaceuticals, supporting major corporate transactions, multiple product launches, significant financings, and all legal, compliance, and business development for a commercial organization generating over $400 million annually. Earlier in his career, he held senior legal roles at Flexion Therapeutics, AVEO Pharmaceuticals, and Oscient Pharmaceuticals, after beginning his legal career at Mintz. Mr. Vittiglio holds a J.D. from Northeastern University School of Law and a B.A. in International Relations from Tufts University.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251208185366/en/

Investor Contact

Laurence Watts

New Street Investor Relations

laurence@newstreetir.com

Media Contact

Julia Deutsch

Lyra Strategic Advisory

Jdeutsch@lyraadvisory.com

Source: PepGen Inc.